TP53 and lip and oral cavity carcinoma: These findings underscore potential clinical implications for OPLs with p53 GOF mutations which may not respond to PD-1 blockade and suggest that p53 status may be a relevant molecular biomarker to predict response in oral cancer immunoprevention.